Ted Falk on Questions on the Order Paper

With regard to those fatalities and serious adverse events (SAEs) associated with Pfizer's and Moderna's COVID-19 mRNA-based vaccines and tracked by Health Canada (HC) and the Public Health Agency of Canada (PHAC): (a) did HC or the PHAC or any other federal agency or entity or agency contracted by the federal government detect a safety signal when examining, (i) the VAERS data from the USA, (ii) the EudraVigilance data from Europe, (iii) the Yellow Card data from England; (b) if the answer to (a) is affirmative for either (i), (ii) or (iii), what are the safety issues and how is the federal government addressing them; (c) what are the respective provincial numbers of vaccine-associated fatal and non­fatal heart attacks, strokes and other cardiovascular events recorded in Canada's vaccine surveillance program(s), between December 31, 2020 and December 31, 2023; (d) given the data from (c), has HC, the PHAC, or another federal government body such as the Canadian Institute for Health Information (CIHI) undertaken the research to determine if there has been an increase in the events described in (c) compared with their baseline values prior to the COVID-19 vaccine roll-outs; (e) what does the temporal association between the fatal or non-fatal serious adverse events in (c) and the timing of the mRNA­based vaccine roll-outs (primary series and boosters) show, per age group; (f) has the submission of any provincial health agencies' reports of vaccine-associated fatalities been denied by Canada's vaccine surveillance program(s); (g) if the answer to (f) is affirmative, how many reports of fatalities were denied by Canada's vaccine surveillance program(s) and for what reasons; (h) how many fatalities and SAEs associated with any drug or medical devices removes that item from the market; (i) how many fatalities and SAEs associated the mRNA-based vaccines will be deemed sufficient, as a threshold safety signal, to shut down the distribution of the mRNA products and what agency has established this benchmark; and (j) in consideration of cumulative reports of fatalities and SAEs during Pfizer's 3-month post-marketing phase, and in Canada and other jurisdictions around the world associated with the mRNA products, why was this vaccination program permitted to continue and who made that decision?